Li XingYu

Li XingYu

Auto-generated profile, based on publicly available information

Li XingYu

Affiliation The Third Clinical College of Zhejiang University of Traditional Chinese Medicine, Hangzhou, Zhejiang, Peoples R China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 May 2025 in PLOS ONE
Verified
Journal Article
Open access
PDF file
PJPan JiaoYi
Pan JiaoYi
SYSun YongQi
Sun YongQi
GKGuo KeChun
Guo KeChun
LXLi XingYu
Li XingYu
LZLiu ZeZhong
Liu ZeZhong
XWXiaofeng Wang
Xiaofeng Wang
Introduction: Osteoarthritis (OA) as a degenerative disease, has seen a continuous rise in incidence and prevalence globally since 1990, imposing a significant disease burden. NSAIDs (Nonsteroidal anti-inflammatory drugs) as symptomatic medications for OA treatment, hold an indispensable position in clinical practice. Objective: To evaluate the efficacy and safety of different NSAIDs in the treatment of OA through Bayesian Network Meta-Analysis (NMA). Methods: Randomized controlled trials (RCTs) on NSAIDs for OA treatment were retrieved from PubMed, Web of Science, Embase, and the Cochrane Library databases. The search timeframe was from the inception of each database up to June 1, 2024. Outcome indicators for NMA were all conducted using a random-effects model. MetaInsight and Stata 14.0 software were used in R for calculations and plotting of NMA. Measurement data were represented by mean difference (MD), and count data by odds ratio (OR); a 95% confidence interval (CI) was also calculated for each effect size. Results: This study included 31 studies, involving 68,539 patients with knee osteoarthritis (KOA) and 16 interventions. NMA results showed that compared to the placebo, Tiaprofenic reduced the VAS score (MD = -0.16, 95% CI: (-0.46 to 0.14), P > 0.05), albeit without significant difference; meanwhile, Diclofenac reduced the total WOMAC score in KOA patients (MD = -0.41, 95% CI: -1.05 to 0.24, P > 0.05). Compared to the placebo, Etoricoxib was the best medication for improving the WOMAC pain subscale score (MD = -0.44; 95% CI: -0.61 to -0.26); Naproxen significantly improved the WOMAC Function score in KOA patients after administration (MD = -0.43; 95% CI: -0.82 to -0.04); Diclofenac intervention significantly reduced the WOMAC Stiffness score in KOA patients (MD = -0.40; 95% CI: -0.67 to -0.13). In terms of adverse event rates, compared to the placebo, the use of Etoricoxib significantly increased the incidence of cardiovascular adverse events (OR = 0.56, 95% CI: 0.32–0.99); Ketoprofen had fewer gastrointestinal adverse events during the medication process (OR = 0.09, 95% CI: 0.04–0.20); Licofelone had a lower rate of other adverse events during the medication process (OR = 0.80, 95% CI: 0.45–1.40, P > 0.05). Therefore, the results indicate that Etoricoxib, Tiaprofenic, Naproxen, Diclofenac, and Ketoprofen have better clinical efficacy and safety. Conclusion: Compared to other NSAIDs, Etoricoxib, Tiaprofenic, Naproxen, and Diclofenac play a more effective role in improving clinical symptoms of OA; in terms of reducing the incidence of adverse events, Ketoprofen has a lower chance of adverse events. However, the possibility of these results still needs further clinical and basic research for verification.